Innate PharmaIPHA 41 Current Ratio is 1.27 as of Dec. 2025, which is 44% below its 10-year median of 2.28. GuruFocus rates IPHA with a GF Score™ of 41/100 and a GF Value™ of $0.16 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,417 Biotechnology companies, Innate Pharma ranks worse than 80.03% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Innate Pharma's current ratio for the quarter that ended in Dec. 2025 was 1.27.
Innate Pharma has a current ratio of 1.27. It generally indicates good short-term financial strength.
The historical rank and industry rank for Innate Pharma's Current Ratio or its related term are showing as below:
IPHA'
s Current Ratio Range Over the Past 10 Years
Min: 1.27 Med: 2.28 Max: 3.81
Current: 1.27
During the past 13 years, Innate Pharma's highest Current Ratio was 3.81. The lowest was 1.27. And the median was 2.28.
IPHA's Current Ratio is ranked worse than 80.03% of 1417
companies
in the Biotechnology industry
Industry Median: 3.89
vs IPHA: 1.27
Innate Pharma (NAS:IPHA) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Innate Pharma Current Ratio Related Terms
Innate Pharma Current Ratio Historical Data
* Premium members only.
The historical data trend for Innate Pharma's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IPHA vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, Innate Pharma's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Innate Pharma Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Innate Pharma's Current Ratio distribution charts can be found below:
* The bar in red indicates where Innate Pharma's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Innate Pharma (IPHA) has a Current Ratio of 1.27 as of Dec. 2025. This is 44% below median its historical median of 2.28. Over the past decade, Innate Pharma's Current Ratio has ranged from 1.27 to 3.81. According to the industry distribution chart, Innate Pharma ranks #1134 out of 1417 companies in the Biotechnology industry, placing it in the top 80%.
Is Innate Pharma's Current Ratio too high?
Innate Pharma's current Current Ratio of 1.27 is 44% below median its 10-year median of 2.28. Over the past 10 years, this metric has ranged from a low of 1.27 to a high of 3.81. The Biotechnology industry median Current Ratio is 3.89. Innate Pharma's value of 1.27 is 67.4% below this industry median. Based on the distribution chart, Innate Pharma ranks #1134 out of 1417 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Innate Pharma has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Innate Pharma's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Innate Pharma ranks #1134 out of 1417 companies for Current Ratio. This places Innate Pharma in the lower half of its industry. The industry median Current Ratio is 3.89. Innate Pharma's value of 1.27 is 67.4% below this benchmark. Historically, Innate Pharma's own Current Ratio has ranged from 1.27 to 3.81 over the past decade. While the company's 10-year median is 2.28 vs. the industry median of 3.89, Innate Pharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Innate Pharma's current Current Ratio of 1.27 is 67.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Innate Pharma's current Current Ratio is 1.27, which is 44% below median its own 10-year median of 2.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innate Pharma stock overvalued right now?
Based on GuruFocus' analysis, Innate Pharma (IPHA) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.16, compared to a current price of $1.90 — trading 1087.5% above its estimated fair value. The current Current Ratio is 1.27, which is 44% below median its 10-year median of 2.28 and 67.4% below the Biotechnology industry median of 3.89. Innate Pharma's overall GF Score™ is 41/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Innate Pharma (IPHA), the current Current Ratio is 1.27 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Innate Pharma (IPHA) Overvalued in 2026?
Based on GuruFocus' analysis, Innate Pharma stock appears to be overvalued.
The current stock price of $1.90 is trading 1087.5% above its estimated GF Value™ of $0.16.
GuruFocus considers Innate Pharma to be Significantly Overvalued.
Key valuation signals for IPHA:
Current Ratio: 1.27 (44% below median its 10-year median of 2.28)
GF Value™: $0.16 vs. price of $1.90 (1087.5% above fair value)
Industry Position: 67.4% below the Biotechnology median (#1134 of 1417)
No single metric tells the full story. See the IPHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.
41GF Score
Get the complete analysis for IPHA
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IPHA has been successfully added to your 
